Sol-Gel Technologies Q3 2023 Earnings Report

Sol-Gel Technologies EPS Results

• Actual EPS: -$2.10
• Consensus EPS: -$2.30
• Beat/Miss: Beat by +$0.20
• One Year Ago EPS: N/A

Sol-Gel Technologies Revenue Results

• Actual Revenue: $0.21 million
• Expected Revenue: $0.70 million
• Beat/Miss: Missed by -$490.00 thousand
• YoY Revenue Growth: N/A

Sol-Gel Technologies Announcement Details

• Quarter: Q3 2023
• Date: 11/9/2023
• Time: N/A
• Conference Call Date: Thursday, November 9, 2023
• Conference Call Time: 7:00AM ET

Sol-Gel Technologies (NASDAQ:SLGL), together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.